/
OSTX
$1.60-$0.01 (-0.62%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$73.5M
46M shares
52-week range
$1.15 – $2.57
32% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Change$-0.91
OS Therapies Incorporated
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
www.ostherapies.com- Employees
- 5
- IPO / List date
- Aug 1, 2024
- HQ
- ROCKVILLE, MD
Held by traders on TradeandTell
No one on the platform currently holds OSTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in OSTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OSTX yet.
